Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 191, Issue 2, Pages 291-302
Publisher
Springer Science and Business Media LLC
Online
2021-10-30
DOI
10.1007/s10549-021-06423-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
- (2021) Haiyan Wang et al. Science Advances
- Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
- (2021) Romualdo Barroso-Sousa et al. BIODRUGS
- LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
- (2021) J. Cortés et al. ANNALS OF ONCOLOGY
- Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
- (2020) Colin G. Buss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
- (2020) Juniper A Scribner et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Emerging nanomedicines for effective breast cancer immunotherapy
- (2020) Amirhossein Bahreyni et al. JOURNAL OF NANOBIOTECHNOLOGY
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
- (2020) Julius Strauss et al. Journal for ImmunoTherapy of Cancer
- PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
- (2019) Samaresh Sau et al. Cancers
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- The emerging role of epigenetic therapeutics in immuno-oncology
- (2019) Michael J. Topper et al. Nature Reviews Clinical Oncology
- Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
- (2019) Claire Vanpouille-Box et al. NATURE REVIEWS DRUG DISCOVERY
- Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
- (2019) Deepak Mittal et al. OncoImmunology
- Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
- (2019) Tyler R. McCaw et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
- (2019) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy
- (2019) Anujan Ramesh et al. BIOMATERIALS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
- (2018) MAKOTO KUBO et al. ANTICANCER RESEARCH
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
- (2018) Cesar August Santa-Maria et al. Oncotarget
- Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
- (2018) Shicheng Su et al. CELL
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innate immune signaling and regulation in cancer immunotherapy
- (2016) Leticia Corrales et al. CELL RESEARCH
- Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3
- (2015) Haruhiko Kamada et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- Nanoparticle-Based Immunotherapy for Cancer
- (2014) Kun Shao et al. ACS Nano
- Probody therapeutics for targeting antibodies to diseased tissue
- (2014) Krishna R Polu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Myeloid-derived suppressor cells in breast cancer
- (2013) Joseph Markowitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started